Iontophoretic Microneedle Patch for Precise, Painless Transdermal Delivery (Iontophoretic Microneedle Device, Tech ID 19-021:
Technology Overview: This technology integrates microneedle arrays with iontophoresis to achieve precise, minimally invasive transdermal drug delivery. The microneedles create micro‑channels in the stratum corneum, while controlled electric fields drive charged therapeutics across the skin at programmable rates. The platform supports small molecules, peptides, and vaccines, enabling clinic‑grade dosing without hypodermic needles.
Industry Pain Point: Oral and injectable routes face low bioavailability, pain, and adherence challenges.
NJIT Solution: Painless, controllable transdermal delivery that improves bioavailability and user compliance.
Key Features & Advantages
- Combined microneedle + iontophoretic control
- Programmable flux for individualized dosing
- Reduced pain and sharps waste
- Portable, patch‑like form factor
Development Stage: TRL 4–5 – Functional prototypes and benchtop validation.
Target Markets
- Transdermal therapeutics & vaccines
- Home‑based drug delivery
- Pediatric/needle‑averse care
Market Opportunity
- Microneedle/transdermal devices (2026): ~$6–8B • CAGR: ~8–10% • 2035: ~$12–15B
Commercial & IP Details
Inventors: James Paul Ronnander, Lauren Simon